StreetInsider.com News Articles

Qiagen NV (QGEN) PT Raised to $40 at Stifel

Fri, 07 Aug 2026 10:28:19 -0400

Stifel analyst Daniel Arias raised the price target on Qiagen NV (NYSE: QGEN) to $40.00 (from $36.00) while maintaining a Hold rating.

Qiagen NV (QGEN) PT Raised to $50 at JPMorgan

Fri, 07 Aug 2026 09:09:28 -0400

JPMorgan analyst Casey Woodring raised the price target on Qiagen NV (NYSE: QGEN) to $50.00 (from $45.00) while maintaining a Overweight rating.

Form 6-K QIAGEN N.V. For: Jun 30

Fri, 07 Aug 2026 06:18:00 -0400

si-local-file:///var/storage/secattach/20260807/26886994.html

Form 6-K QIAGEN N.V. For: Jun 30

Fri, 07 Aug 2026 06:18:00 -0400

si-local-file:///var/storage/secattach/20260807/26886994.html

Form 6-K QIAGEN N.V. For: Jun 30

Fri, 07 Aug 2026 06:18:00 -0400

si-local-file:///var/storage/secattach/20260807/26887045.html

Form 6-K QIAGEN N.V. For: Jun 30

Fri, 07 Aug 2026 06:18:00 -0400

si-local-file:///var/storage/secattach/20260807/26887045.html

Form 6-K QIAGEN N.V. For: Jun 30

Fri, 07 Aug 2026 06:17:00 -0400

si-local-file:///var/storage/secattach/20260807/26886915.html

Form 6-K QIAGEN N.V. For: Jun 30

Fri, 07 Aug 2026 06:17:00 -0400

si-local-file:///var/storage/secattach/20260807/26886915.html

Qiagen NV (QGEN) PT Raised to $40 at Barclays

Fri, 07 Aug 2026 04:55:21 -0400

Barclays analyst Luke Sergott raised the price target on Qiagen NV (NYSE: QGEN) to $40.00 (from $38.00) while maintaining a Equalweight rating.

QIAGEN NV (QIA:GR) (QGEN) PT Raised to EUR40 at Morgan Stanley

Fri, 07 Aug 2026 03:59:28 -0400

Morgan Stanley analyst Aisyah Noor raised the price target on QIAGEN NV (QIA:GR) (NYSE: QGEN) to EUR40.00 (from EUR37.00) while maintaining a Overweight rating.

QIAGEN NV (QIA:GR) (QGEN) PT Raised to EUR40 at Morgan Stanley

Fri, 07 Aug 2026 03:59:28 -0400

Morgan Stanley analyst Aisyah Noor raised the price target on QIAGEN NV (QIA:GR) (NYSE: QGEN) to EUR40.00 (from EUR37.00) while maintaining a Overweight rating.

QIAGEN NV (QIA:GR) (QGEN) PT Raised to EUR40 at Morgan Stanley

Fri, 07 Aug 2026 03:59:28 -0400

Morgan Stanley analyst Aisyah Noor raised the price target on QIAGEN NV (QIA:GR) (NYSE: QGEN) to EUR40.00 (from EUR37.00) while maintaining a Overweight rating.

QIAGEN NV (QIA:GR) (QGEN) PT Raised to EUR40 at Morgan Stanley

Fri, 07 Aug 2026 03:59:28 -0400

Morgan Stanley analyst Aisyah Noor raised the price target on QIAGEN NV (QIA:GR) (NYSE: QGEN) to EUR40.00 (from EUR37.00) while maintaining a Overweight rating.

Qiagen NV (QGEN) PT Raised to $48 at Jefferies

Thu, 06 Aug 2026 15:23:08 -0400

Jefferies analyst Tycho Peterson raised the price target on Qiagen NV (NYSE: QGEN) to $48.00 (from $46.00) while maintaining a Buy rating.

Qiagen (QGEN) spreader of 1500 contracts of August 45 and 3K contracts of September 45 calls

Thu, 06 Aug 2026 14:18:54 -0400

Qiagen (NYSE: QGEN) 30-day call option implied volatility is 47; compared to its 52-week range of 18 to 59 with a focus on a spreader of 1500 contracts of August 45 and 3K contracts of September 45 calls.

Qiagen (QGEN) Tops Q2 EPS by 2c

Wed, 05 Aug 2026 16:43:55 -0400

Qiagen (NYSE: QGEN) reported Q2 EPS of $0.62, $0.02 better than the analyst estimate of $0.60. Revenue for the quarter came in at $535 million versus the consensus estimate of $530.77 million.

For earnings history and earnings-related data on Qiagen (QGEN) click here.

Qiagen tops Q2 outlook with flat sales, reaffirms 2026 guidance

Wed, 05 Aug 2026 16:05:55 -0400

QIAGEN N.V. (NYSE: QGEN) reported net sales of $535 million for its second quarter of fiscal 2026, unchanged from the same period a year earlier on both a reported and constant exchange rate (CER) basis, according to a company statement. The result exceeded the company's prior outlook for an approximately 2% CER decline.

The company's growth pillars collectively delivered approximately 5% CER growth during the quarter. Sample technologies led the gains, with consumables growing at a high single-digit CER rate and instruments at a mid-single-digit CER rate. QIAcuity and QIAGEN Digital Insights also contributed to growth. QuantiFERON sales rose 1% CER,

Qiagen tops Q2 outlook with flat sales, reaffirms 2026 guidance

Wed, 05 Aug 2026 16:05:55 -0400

QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook

Wed, 05 Aug 2026 16:05:00 -0400

Q2 2026 results:
- Net sales of $535 million unchanged compared with Q2 2025 on a reported basis and at constant exchange rates (CER), exceeding the outlook for an about 2% CER decline
- Growth pillars deliver about 5% CER growth, led by Sample technologies, QIAcuity and QDI; QuantiFERON sales rise slightly amid lower U.S. immigration testing demand
- Adjusted operating income margin of 29.4%, maintaining a high level of profitability
- Diluted EPS of $0.50; adjusted diluted EPS of $0.62 on a reported and CER basis, above the outlook for at least $0.60 CER
H1 2026 operating cash of $301 million remains at a strong level

QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook

Wed, 05 Aug 2026 16:05:00 -0400

Q2 2026 results:

Net sales of $535 million unchanged compared with Q2 2025 on a reported basis and at constant exchange rates (CER), exceeding the outlook for an about 2% CER decline

Growth pillars deliver about 5% CER growth, led by Sample technologies, QIAcuity and QDI; QuantiFERON sales rise slightly amid lower U.S. immigration testing demand

Adjusted operating income margin of 29.4%, maintaining a high level of profitability

Diluted EPS of $0.50; adjusted diluted EPS of $0.62 on a reported and CER basis, above the outlook for at least $0.60 CER

H1 2026 operating cash of $301 million remains at a strong level

QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook

Wed, 05 Aug 2026 16:05:00 -0400

Q2 2026 results:

Net sales of $535 million unchanged compared with Q2 2025 on a reported basis and at constant exchange rates (CER), exceeding the outlook for an about 2% CER decline

Growth pillars deliver about 5% CER growth, led by Sample technologies, QIAcuity and QDI; QuantiFERON sales rise slightly amid lower U.S. immigration testing demand

Adjusted operating income margin of 29.4%, maintaining a high level of profitability

Diluted EPS of $0.50; adjusted diluted EPS of $0.62 on a reported and CER basis, above the outlook for at least $0.60 CER

H1 2026 operating cash of $301 million remains at a strong level

QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook

Wed, 05 Aug 2026 16:05:00 -0400

Q2 2026 results:

Net sales of $535 million unchanged compared with Q2 2025 on a reported basis and at constant exchange rates (CER), exceeding the outlook for an about 2% CER decline

Growth pillars deliver about 5% CER growth, led by Sample technologies, QIAcuity and QDI; QuantiFERON sales rise slightly amid lower U.S. immigration testing demand

Adjusted operating income margin of 29.4%, maintaining a high level of profitability

Diluted EPS of $0.50; adjusted diluted EPS of $0.62 on a reported and CER basis, above the outlook for at least $0.60 CER

H1 2026 operating cash of $301 million remains at a strong level

QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook

Wed, 05 Aug 2026 16:05:00 -0400

Q2 2026 results:

Net sales of $535 million unchanged compared with Q2 2025 on a reported basis and at constant exchange rates (CER), exceeding the outlook for an about 2% CER decline

Growth pillars deliver about 5% CER growth, led by Sample technologies, QIAcuity and QDI; QuantiFERON sales rise slightly amid lower U.S. immigration testing demand

Adjusted operating income margin of 29.4%, maintaining a high level of profitability

Diluted EPS of $0.50; adjusted diluted EPS of $0.62 on a reported and CER basis, above the outlook for at least $0.60 CER

H1 2026 operating cash of $301 million remains at a strong level

QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook

Wed, 05 Aug 2026 16:05:00 -0400

Q2 2026 results:

Net sales of $535 million unchanged compared with Q2 2025 on a reported basis and at constant exchange rates (CER), exceeding the outlook for an about 2% CER decline

Growth pillars deliver about 5% CER growth, led by Sample technologies, QIAcuity and QDI; QuantiFERON sales rise slightly amid lower U.S. immigration testing demand

Adjusted operating income margin of 29.4%, maintaining a high level of profitability

Diluted EPS of $0.50; adjusted diluted EPS of $0.62 on a reported and CER basis, above the outlook for at least $0.60 CER

H1 2026 operating cash of $301 million remains at a strong level

Citi Assumes Qiagen NV (QGEN) at Neutral

Thu, 30 Jul 2026 10:03:20 -0400

Citi analyst Brendan Digan assumes coverage on Qiagen NV (NYSE: QGEN) with a Neutral rating and a price target of $38.00.

For an analyst ratings summary and ratings history on Qiagen NV click here. For more ratings news on Qiagen NV click here.

Shares of Qiagen NV closed at $41.81 yesterday.